newsfilter
← Latest News
GlobeNewswire·

AEON Biopharma Announces FDA Feedback Following BPD Type 2a Meeting for the ABP-450 Biosimilar Program

  • FDA provided constructive feedback on AEON Biopharma's analytical similarity strategy for ABP-450 under the 351(k) biosimilar pathway following a successful Type 2a meeting in January 2026.
  • The Agency acknowledged the scientific challenges of characterizing the 900 kDa botulinum neurotoxin complex but noted that AEON's analytical methodologies are reasonable for advancing the program.
  • AEON plans to complete the majority of its analytical comparability program in 2026 based on the FDA's feedback.
  • The company intends to request a BPD Type 2b meeting with the FDA in 2026 to discuss next steps for ABP-450 as a biosimilar to BOTOX ® across all approved therapeutic indications.
  • ABP-450 is a prabotulinumtoxinA biosimilar to BOTOX ® (onabotulinumtoxinA) manufactured by Daewoong Pharmaceutical at a facility authorized by the FDA, Health Canada, and the EMA.
  • ABP-450 is currently approved as a biosimilar in India, Mexico, and the Philippines, while AEON holds exclusive development rights for therapeutic indications in the U.S., Canada, the EU, the UK, 6and other international territories.
  • Rob Bancroft, CEO of AEON, stated that the FDA's feedback reinforces confidence in the analytical work 6and the capital-efficient path toward full-label regulatory approval.